<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

    Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)

    VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.

    Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

    Biodesix to Present at 2011 Biotech Showcase

    Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA

    Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.

    VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.

    Biodesix Selected as a Colorado Company to Watch

    Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.

    Biodesix Secures $10 Million in Series B-1 Funding

    Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.

    Biodesix Receives Certification from NY State

    Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.

    Biodesix Completes Series C Financing and Receives Grant

    Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.